Oncology Pharma Inc. (ONPH)
OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
At close: May 30, 2025
9,900%
Market Cap 3.87K
Revenue (ttm) 10.21K
Net Income (ttm) 186.04K
Shares Out 38.66M
EPS (ttm) n/a
PE Ratio 0.02
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 8,692
Average Volume 2,193
Open 0.0001
Previous Close 0.0001
Day's Range 0.0001 - 0.0001
52-Week Range n/a
Beta -18.56
RSI 49.78
Earnings Date n/a

About Oncology Pharma

Oncology Pharma Inc., an oncology company, develops, manufactures, and commercializes therapeutics. The company has a collaboration and licensing agreement with Kalos Therapeutics Inc. for exploring treatment opportunities of the COVID-19 virus. The company was formerly known as SourcingLink.net Inc. and changed its name to Oncology Pharma Inc. in June 2019. Oncology Pharma Inc. was incorporated in 1993 and is based in San Francisco, California. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1993
Employees 1
Stock Exchange OTCMKTS
Ticker Symbol ONPH
Full Company Profile

Financial Performance

In 2012, Oncology Pharma's revenue was $10,214, a decrease of -92.42% compared to the previous year's $134,700. Earnings were $186,035, an increase of 216.79%.

Financial Statements

News

Median Technologies Partners with a Top 10 Oncology Pharma Company to Apply AI for Imaging Biomarker Discovery

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Median Technologies Partners with a Top 10 Oncology Pharma Company to Apply AI for Imaging Biomarker Discovery.

10 months ago - Business Wire

Oncology Pharma Conducting Interviews and Presentations with Investors to Pursue Next Steps to Forward The Development Process of Nanoemulsion Drug Delivery System

SAN FRANCISCO, CA / ACCESSWIRE / July 12, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") is furthering progress in discussions with investors and developing the fi...

3 years ago - Accesswire

Oncology Pharma Conducting All The Preparations to Take Steps to Forward The Development Process of Nanoemulsion Drug Delivery System

SAN FRANCISCO, CA / ACCESSWIRE / June 29, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") is pleased to be reviewing the financing for taking the steps on moving fo...

3 years ago - Accesswire

Oncology Pharma Announces: Initial Feasibility Study of the Nanoemulsion Drug Delivery System is Complete and Results Have Met the Threshold for Moving Forward To the Next Steps of Development

SAN FRANCISCO, CA / ACCESSWIRE / June 8, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") is pleased that the initial feasibility stage is complete and results have ...

3 years ago - Accesswire

Oncology Pharma Advances Progress on Multiple Fronts Including Advanced Attention to Connect2Trials' Commercial Development

SAN FRANCISCO, CA / ACCESSWIRE / May 9, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") is pleased to execute its next phase with Connect2Trials, Inc. Originally, t...

3 years ago - Accesswire

Oncology Pharma Completes Feasibility Phase of its Licensed Nanoemulsion Drug Delivery System to Treat Cancer

SAN FRANCISCO, CA / ACCESSWIRE / April 13, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma ("The Company") is pleased to announce that it has completed the initial feasibility phase of its...

3 years ago - Accesswire

Oncology Pharma Reports on Progress with Ribera Solutions

SAN FRANCISCO, CA / ACCESSWIRE / March 2, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") is pleased to announce progress with its investment with Ribera Solutions'...

3 years ago - Accesswire

Oncology Pharma Releases Further Feasibility Studies, Data and Capacities

SAN FRANCISCO, CA / ACCESSWIRE / February 23, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") looks toward releasing further results of the studies under the Co-Dev...

3 years ago - Accesswire

Oncology Pharma Expands on Feasibility Studies and Data

SAN FRANCISCO, CA / ACCESSWIRE / February 17, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") wants to expand on a previously announced press release that included ...

3 years ago - Accesswire

Oncology Pharma, Inc. and Regen BioPharma, Inc. Announce Intent to Jointly Fast Track Development of Modified mRNA anti-Cancer Vaccine

SAN FRANCISCO, CA / ACCESSWIRE / February 14, 2022 / Oncology Pharma, Inc. ("The Company") (OTC PINK:ONPH) and Regen BioPharma, Inc. (OTC PINK:RGBP) and (OTC PINK:RGBPP): announced that they intend to...

3 years ago - Accesswire

Oncology Pharma Gives Update on Technology, Formulation and Data Creation

SAN FRANCISCO, CA / ACCESSWIRE / February 8, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") is pleased to announce that the co-development agreement and ongoing wo...

3 years ago - Accesswire

Oncology Pharma's New Year Update

SAN FRANCISCO, CA / ACCESSWIRE / January 10, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") update on its progress to kick off the new year. The Company has advanc...

3 years ago - Accesswire

Oncology Pharma Meeting Towards Future Developments

SAN FRANCISCO, CA / ACCESSWIRE / December 17, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. ("The Company") conducted a meeting with the Board of Directors, executives, and Scienti...

3 years ago - Accesswire

Oncology Pharma Year End Review and Outlook

SAN FRANCISCO, CA / ACCESSWIRE / December 9, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") and its Chief Executive are pleased to give a year end update and provi...

3 years ago - Accesswire

Oncology Pharma Research and Vision

SAN FRANCISCO, CA / ACCESSWIRE / November 30, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") is a pioneering oncology company dedicated to providing the financing ...

3 years ago - Accesswire

Oncology Pharma Reveals Plans for Development of Lead Cancer Drug Candidate

SAN FRANCISCO, CA / ACCESSWIRE / November 8, 2021 / Oncology Pharma, Inc. (the "Company") is pleased to provide some insight into the progress of its co-development project with NanoSmart Pharmaceutic...

3 years ago - Accesswire

Oncology Pharma, Inc. Gives Update on Ongoing Work and Progress

SAN FRANCISCO, CA / ACCESSWIRE / October 27, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Pursuant to previous communications, Oncology Pharma, Inc. (the "Company") is making progress towards pursuing ...

3 years ago - Accesswire

Oncology Pharma, Inc. Has Engaged a PCAOB Audit Firm Looking Towards Moving the Company Towards a Senior Listing

SAN FRANCISCO, CA / ACCESSWIRE / October 15, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Pursuant to previously announced press release, Oncology Pharma, Inc. (the "Company") has retained the services...

3 years ago - Accesswire

Oncology Pharma, Inc. Update on PCAOB Audit Selection Process and License Agreement

SAN FRANCISCO, CA / ACCESSWIRE / October 12, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. (the "Company") would like to update investors on its progress. The Company is in the fin...

3 years ago - Accesswire

Oncology Pharma, Inc. Has Received the Committed Funding to Perform All Necessary IND-Enabling Preclinical Work for Its First Lead Candidate, a Dactinomycin Nanoemulsion Drug Product

SAN FRANCISCO, CA / ACCESSWIRE / September 13, 2021 / Oncology Pharma, Inc. (OTC PINK:ONPH). In keeping with management's commitment to continue implementation of Oncology Pharma's ("the Company") cap...

4 years ago - Accesswire

Oncology Pharma's Co-Development Agreement Pursues Strategic and Direct Objectives

SAN FRANCISCO, CA / ACCESSWIRE / August 23, 2021 / Oncology Pharma, Inc. (OTC PINK:ONPH) defines its objective and strategy for recently signed Co-Development deal. The primary goal of the Co-Developm...

4 years ago - Accesswire

Oncology Pharma, Inc. Executes Co-Development Agreement with NanoSmart Pharmaceuticals, Inc.

SAN FRANCISCO, CA / ACCESSWIRE / August 19, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) With much anticipation, Oncology Pharma, Inc. has finalized a Co-Development Agreement with NanoSmart Pharmaceut...

4 years ago - Accesswire

Oncology Pharma, Inc. To Move to Conducting Trials on Licensed IP

SAN FRANCISCO, CA / ACCESSWIRE / July 20, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. (the "Company") is laying out and taking necessary steps to move its licensed IP forward. Fr...

4 years ago - Accesswire

Oncology Pharma, Inc. is Entering Into the Next Phase of its Growth and Expansion Phase

SAN FRANCISCO, CA / ACCESSWIRE / June 30, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. (the "Company") is developing a program to establish the use of its license utilizing NR2F6 ...

4 years ago - Accesswire

Shares of This Biotech Stock Could Jump 437%

Published by: Tim Kraimer Oncology Pharma, Inc. (Symbol: ONPH) is a San Francisco-based biotech company that has been making one blockbuster announcement after the next. These announcements have sent ...

4 years ago - TheFinancialNews